
USA - NASDAQ:MGTA - US55910K1088 - Common Stock
ChartMill assigns a Buy % Consensus number of 43% to MGTA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating | 
|---|---|---|---|
| 2023-02-28 | HC Wainwright & Co. | Initiate | Neutral | 
| 2023-01-26 | BTIG | Downgrade | Buy -> Neutral | 
| 2023-01-26 | Cowen & Co. | Downgrade | Outperform -> Market Perform | 
| 2023-01-26 | Wedbush | Downgrade | Outperform -> Neutral | 
| 2022-12-21 | BTIG | Maintains | Buy | 
| 2022-08-25 | Goldman Sachs | Downgrade | Buy -> Neutral | 
| 2022-05-24 | Goldman Sachs | Maintains | Buy | 
| 2022-04-18 | Mizuho | Maintains | Buy | 
| 2022-04-18 | BTIG | Maintains | Buy | 
| 2022-01-24 | B. Riley Securities | Maintains | Buy | 
| 2022-01-06 | Goldman Sachs | Upgrade | Neutral -> Buy | 
| 2021-08-03 | JP Morgan | Downgrade | Overweight -> Neutral | 
| 2021-06-29 | Cantor Fitzgerald | Initiate | Overweight | 
| 2021-06-15 | BTIG | Initiate | Buy | 
| 2021-05-18 | B. Riley Securities | Initiate | Buy | 
6 analysts have analysed MGTA and the average price target is 1.02 USD. This implies a price increase of 45.8% is expected in the next year compared to the current price of 0.6996.
The consensus rating for MAGENTA THERAPEUTICS INC (MGTA) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
The number of analysts covering MAGENTA THERAPEUTICS INC (MGTA) is 6.